-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Opinion|Videos|May 8, 2024

Clinical Evidence for Emerging PAH Therapies

Dr Oudiz discusses clinical data that support the efficacy and safety of emerging PAH therapies and ongoing research in the treatment space.

Video content above is prompted by the following questions:

  • What clinical data support the efficacy and safety of these new treatments, and how do they compare to existing therapies?
  • Are there any ongoing clinical trials evaluating promising investigational agents or combination therapies for pulmonary arterial hypertension (PAH)?

Related to this article

Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.